GSA Capital Partners LLP lowered its position in Xencor, Inc. (NASDAQ:XNCR) by 33.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,800 shares of the biopharmaceutical company’s stock after selling 19,300 shares during the quarter. GSA Capital Partners LLP owned approximately 0.08% of Xencor worth $819,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of XNCR. Equitec Specialists LLC bought a new stake in Xencor in the second quarter worth approximately $116,000. SG Americas Securities LLC increased its stake in shares of Xencor by 62.6% during the 2nd quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 3,252 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Xencor by 4.5% during the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 385 shares during the last quarter. Airain ltd increased its stake in shares of Xencor by 49.9% during the 2nd quarter. Airain ltd now owns 13,360 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 4,447 shares during the last quarter. Finally, Clinton Group Inc. increased its stake in shares of Xencor by 4.6% during the 1st quarter. Clinton Group Inc. now owns 15,987 shares of the biopharmaceutical company’s stock worth $382,000 after purchasing an additional 700 shares during the last quarter. Hedge funds and other institutional investors own 76.92% of the company’s stock.

A number of research analysts have recently weighed in on the stock. Canaccord Genuity restated a “buy” rating and set a $36.00 price target on shares of Xencor in a report on Tuesday, August 8th. ValuEngine upgraded shares of Xencor from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Wedbush reiterated an “outperform” rating and issued a $29.00 price objective on shares of Xencor in a report on Friday, June 16th. BidaskClub cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Finally, Zacks Investment Research downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. Xencor has an average rating of “Hold” and an average target price of $29.33.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/gsa-capital-partners-llp-sells-19300-shares-of-xencor-inc-xncr/1607077.html.

In related news, major shareholder John S. Stafford III purchased 41,016 shares of Xencor stock in a transaction that occurred on Tuesday, August 22nd. The stock was purchased at an average cost of $19.69 per share, with a total value of $807,605.04. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder John S. Stafford III purchased 25,000 shares of Xencor stock in a transaction that occurred on Wednesday, August 16th. The shares were bought at an average cost of $20.96 per share, with a total value of $524,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 215,551 shares of company stock worth $4,386,916. 4.14% of the stock is owned by company insiders.

Xencor, Inc. (NASDAQ XNCR) opened at 23.82 on Wednesday. The firm’s market cap is $1.12 billion. The firm’s 50-day moving average price is $21.71 and its 200 day moving average price is $22.43. Xencor, Inc. has a one year low of $18.45 and a one year high of $29.38.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. The company had revenue of $13.34 million during the quarter, compared to analysts’ expectations of $8.15 million. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%. On average, equities research analysts forecast that Xencor, Inc. will post ($1.17) EPS for the current year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.